Abrysvo

Abrysvo is a vaccine designed to protect against Respiratory Syncytial Virus (RSV). It is administered intramuscularly and is manufactured by Pfizer Europe Ma Eeig. This vaccine targets RSV, subgroup A, stabilized prefusion F protein 847a.

Abrysvo is used for the prevention of Respiratory Syncytial Virus (RSV) infections. RSV is a common respiratory virus that can cause severe illness, particularly in infants and young children. The vaccine is intended to provide immunity against RSV, subgroup A, which is one of the most prevalent strains of the virus. What is Abrysvo used for? It is primarily used to prevent RSV infections, which can lead to conditions such as bronchiolitis and pneumonia.

Common effects of Abrysvo may include localized reactions at the injection site, such as pain, redness, or swelling. Some individuals may also experience general symptoms like fatigue, headache, or muscle pain. These effects are typically mild and temporary, resolving within a few days.

Abrysvo should be administered by healthcare professionals trained in intramuscular injections. It is important to inform your healthcare provider about any allergies or medical conditions before receiving the vaccine. Individuals with a history of severe allergic reactions to any component of the vaccine should avoid its use.

Abrysvo may interact with other medications or vaccines. It is advisable to consult with a healthcare provider before receiving the vaccine if you are taking any other medications. Additionally, the vaccine should not be mixed with other injectable products in the same syringe.